G S Sachin

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent, preventable, and treatable respiratory condition characterized by persistent airflow limitation and respiratory symptoms. The management of COPD requires a comprehensive and individualized approach focused on reducing symptom burden, improving exercise tolerance and quality of life, and decreasing the future risk of exacerbations, hospitalizations, and mortality. For PharmD … Read more

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. Its management requires a comprehensive approach aimed at reducing symptoms, improving exercise tolerance and health status, and preventing and … Read more

Asthma is now recognized as a heterogeneous disease with various underlying mechanisms, moving the field of respiratory care away from a “one-size-fits-all” approach. Personalized medicine in asthma aims to tailor treatment and prevention strategies to the individual patient by using specific phenotypes, endotypes, biomarkers, and pharmacogenomic data. This approach allows for more precise and effective … Read more

The management of chronic asthma is a dynamic process centered on achieving long-term control of symptoms and reducing the risk of future exacerbations, lung function decline, and medication side effects. It involves a partnership between the patient and healthcare provider, utilizing a stepwise approach to pharmacological therapy guided by evidence-based guidelines like those from the … Read more

Muscarinic agents, encompassing both agonists and antagonists, interact with muscarinic acetylcholine receptors (mAChRs) found throughout the body, including the airways, heart, and gastrointestinal tract. In respiratory medicine, muscarinic antagonists (anticholinergics) are particularly important for managing conditions like COPD and asthma by inducing bronchodilation. The chemical structures of these agents are key to their affinity, selectivity, … Read more

Short-acting beta2-agonists (SABAs) are indispensable quick-relief medications for bronchospasm in asthma and Chronic Obstructive Pulmonary Disease (COPD). Their ability to rapidly relax airway smooth muscle is a direct consequence of their chemical structures, which allow for selective interaction with β2-adrenergic receptors. For PharmD students, understanding the medicinal chemistry of SABAs—including their core pharmacophore, structure-activity relationships … Read more

Corticosteroids are a cornerstone in the management of various inflammatory and immune-mediated diseases, including respiratory conditions like asthma and COPD. They are available in oral formulations for systemic effects and inhaled formulations designed to maximize local lung activity while minimizing systemic exposure. The therapeutic efficacy, potency, selectivity, and pharmacokinetic profiles of these agents are intrinsically … Read more

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are prevalent chronic respiratory conditions that significantly impact global health. While they share some similarities, such as airflow limitation, their underlying pathophysiology and, consequently, their pharmacological management strategies differ in key aspects. A thorough understanding of the pharmacology of antiasthmatic and COPD medications—including bronchodilators, anti-inflammatory agents, and newer … Read more